Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Ventrus Biosciences Inc. is ready to take its lead candidate iferanserin, a novel compound aimed at arresting hemorrhoid symptoms rather than soothing them, into Phase III studies after the micro-cap biotech's late-December initial public offering brought in $20 million to support the program.
You may also be interested in...
Like other start-up companies working to develop drugs for GI disorders, Ventrus Biosciences was attracted to the sector not only by unmet clinical needs and the focused sales opportunities, but also by the potential for creating a cross-over success: a drug that launches as a prescription product but eventually leaps over the counter to become a blockbuster, á la Claritin. Ventrus has two drug candidates ready for Phase III testing: a topical gel formulation of diltiazem, a generic vasodilator, as a treatment for anal fissures, and a novel compound it hopes will become the first new product approved for hemorrhoids in 30 years.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.